Last $6.60 USD
Change Today -0.01 / -0.15%
Volume 66.4K
VCYT On Other Exchanges
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

veracyte inc (VCYT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - $19.00
52 Week Low
11/14/14 - $6.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VERACYTE INC (VCYT)

Related News

No related news articles were found.

veracyte inc (VCYT) Related Businessweek News

No Related Businessweek News Found

veracyte inc (VCYT) Details

Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignancy Classifiers for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

115 Employees
Last Reported Date: 03/20/14
Founded in 2006

veracyte inc (VCYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $380.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $201.0K
Chief Operating Officer
Total Annual Compensation: $316.3K
Compensation as of Fiscal Year 2013.

veracyte inc (VCYT) Key Developments

Veracyte, Inc. Reports Unaudited Consolidated Earnings and Operating Results for the Third Quarter and Nine Months Ended September 30, 2014; Reiterates Earnings Guidance for the Full Year 2014

Veracyte, Inc. reported unaudited consolidated earnings and operating results for the third quarter and nine months ended September 30, 2014. For the quarter, revenue was $9.8 million, an increase of 76%, compared to $5.6 million for the third quarter of 2013. Net loss was $7.9 million, or $0.37 per common share, compared to a net loss of $6.3 million, or $6.59 per common share, for the same period in 2013. Loss from operations was $7.81 million compared to $6.10 million a year ago. For the nine months, revenue was $26.0 million, compared to $15.0 million for the same period in 2013, an increase of 73%. Loss from operations was $20.95 million compared to $17.41 million a year ago. Net loss was $21.23 million, or $0.99 per common share compared to a net loss of $19.69 million, or $22.87 per common share for the same period in 2013. The company received 16,781 fine needle aspiration (FNA) samples during the third quarter of 2014, compared to 12,430 FNA samples for the comparable period in 2013, an increase of 35%. The number of GEC tests performed continued within the 20% to 22% range of FNA samples received, demonstrating the company's increasing penetration of institutional accounts. The company reiterates its full-year 2014 guidance for the number of FNA samples received to be in the range of 66,000 to 73,000 FNA samples. The company expects to end 2014 with revenue of approximately $38 million, at the low end of the guided range, reflecting an approximate 74% growth in year-over-year revenue.

Veracyte, Inc. Announces Management Changes

Veracyte, Inc. announced the resignation of Samuel D. Colella from its Board of Directors, effective November 30, 2014. The company selected John L. Bishop to fill the vacancy left by Mr. Colella, effective December 1, 2014. Mr. Bishop will also join the Board's Compensation Committee. Mr. Bishop has a distinguished career in diagnostics and the life sciences industry. He currently serves as chairman and chief executive officer of Cepheid, a leading global molecular diagnostics company, which he joined in 2002.

Veracyte, Inc. to Report Q3, 2014 Results on Nov 13, 2014

Veracyte, Inc. announced that they will report Q3, 2014 results at 5:00 PM, US Eastern Standard Time on Nov 13, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCYT:US $6.60 USD -0.01

VCYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genomic Health Inc $33.17 USD +0.74
Laboratory Corp of America Holdings $100.46 USD -0.18
Response Genetics Inc $0.55 USD +0.03
Rosetta Genomics Ltd $2.53 USD +0.15
TrovaGene Inc $4.85 USD +0.029
View Industry Companies

Industry Analysis


Industry Average

Valuation VCYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERACYTE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at